CML Blast Phase: What to Do When Chemotherapy Combined with Ponatinib Bridge Therapy Does Not Achieve Complete Response
Clinical Scenario
Chronic myeloid leukemia (CML) advances through distinct phases — chronic phase, accelerated phase, and blast phase (BP). Blast phase represents the most aggressive stage of the disease. Initial management of CML blast phase typically involves a combination bridge strategy aimed at achieving a complete response before definitive therapy. When that response is not reached, a structured next-line approach is required.
Prior Therapy & Failure Condition
The preceding treatment line for CML blast phase used a combination of chemotherapy and ponatinib as a bridging strategy, with the primary objective of achieving a complete response.
When this complete response is not achieved, escalation to the next protocol is indicated. The protocol below outlines the evidence-based approach for this situation.
Next-Line Approach (Partial Overview)
The evidence-based strategy at this stage involves allogeneic stem cell transplantation as a central component. The complete protocol — including the specific conditions governing transplantation, the post-transplant maintenance approach, and the full clinical algorithm — is available via the structured regimen link below.
References
DOI: 10.1002/ajh.27443
- CML can be classified into three phases: CP, accelerated phase (AP), and blast phase (BP).
- The only curative option for patients with BP disease is allo-HSCT.
- At MD Anderson, patients with CML-BP are treated with a combination of chemotherapy (type depends on the immunophenotype) and ponatinib followed by allo-HSCT once a complete response is achieved, then given maintenance TKI therapy post-allo-HSCT.
View source ↗